ZTF vs. TET, SYNT, ESNT, CAPD, SLP, CMCL, THS, SHG, ECOR, and AXS
Should you be buying Zotefoams stock or one of its competitors? The main competitors of Zotefoams include Treatt (TET), Synthomer (SYNT), Essentra (ESNT), Capital (CAPD), Sylvania Platinum (SLP), Caledonia Mining (CMCL), Tharisa (THS), Shanta Gold (SHG), Ecora Resources (ECOR), and Accsys Technologies (AXS). These companies are all part of the "basic materials" sector.
Zotefoams (LON:ZTF) and Treatt (LON:TET) are both small-cap basic materials companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment, community ranking and earnings.
Treatt has a net margin of 7.42% compared to Zotefoams' net margin of 7.28%. Zotefoams' return on equity of 8.20% beat Treatt's return on equity.
Treatt has a consensus price target of GBX 655, indicating a potential upside of 36.03%. Given Treatt's higher possible upside, analysts plainly believe Treatt is more favorable than Zotefoams.
In the previous week, Zotefoams had 1 more articles in the media than Treatt. MarketBeat recorded 1 mentions for Zotefoams and 0 mentions for Treatt. Treatt's average media sentiment score of 0.53 beat Zotefoams' score of 0.00 indicating that Treatt is being referred to more favorably in the news media.
Zotefoams pays an annual dividend of GBX 7 per share and has a dividend yield of 1.9%. Treatt pays an annual dividend of GBX 8 per share and has a dividend yield of 1.7%. Zotefoams pays out 3,684.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Treatt pays out 4,444.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Zotefoams is clearly the better dividend stock, given its higher yield and lower payout ratio.
Zotefoams has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Treatt has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.
75.1% of Zotefoams shares are owned by institutional investors. Comparatively, 70.1% of Treatt shares are owned by institutional investors. 18.7% of Zotefoams shares are owned by company insiders. Comparatively, 12.3% of Treatt shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Zotefoams received 87 more outperform votes than Treatt when rated by MarketBeat users. Likewise, 69.49% of users gave Zotefoams an outperform vote while only 68.83% of users gave Treatt an outperform vote.
Treatt has higher revenue and earnings than Zotefoams. Zotefoams is trading at a lower price-to-earnings ratio than Treatt, indicating that it is currently the more affordable of the two stocks.
Summary
Zotefoams beats Treatt on 10 of the 19 factors compared between the two stocks.
Get Zotefoams News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZTF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZTF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zotefoams Competitors List
Related Companies and Tools
